Restriction Endonucleases Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Report Covers Global Restriction Endonuclease Analysis and the market is Segmented by Type (Type I, Type II, Type III, and Type IV), Application (Genetic Engineering, DNA Mapping, Gene Sequencing, and Other Applications), End User (Pharmaceutical and Biotechnology Companies, Academic Research Institutes, and Other End Users), and Geography (North America, Europe, Asia-Pacific, Rest of the World). The Report Offers the Value (USD Million) for the Above Segments.

Restriction Endonucleases Market Size

Restriction Endonucleases Market Summary

Compare market size and growth of Restriction Endonucleases Market with other markets in Healthcare Industry

Restriction Endonucleases Market Analysis

The Restriction Endonucleases Market size is estimated at USD 328.95 million in 2025, and is expected to reach USD 454.30 million by 2030, at a CAGR of 6.67% during the forecast period (2025-2030).

The rising use of restriction endonucleases in various applications and increasing expenditure on research and development by biotechnology and pharmaceutical companies are the key drivers for the market.

The rising use of restriction endonucleases in various applications such as genetic engineering and gene sequencing used for research or treatment purposes and increasing expenditure on research and development by biotechnology and pharmaceutical companies are actively affecting the growth of the studied market. For instance, according to the study published by the Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of Russian Academy of Sciences in September 2023, in modern molecular biological practices restriction enzymes are considered as crucial tools, and currently for obtaining DNA fragments, procedures involving restriction enzymes has become a routine task. Thus, increasing use of restriction endonucleases in the reesearch work is expected to propel the market growth over the forecast period.

Furthermore, the increased funding and investment by biotechnology, pharmaceutical companies, and government organizations for research and innovation in the field of genomics is estimated to propel market growth. For instance, according to the National Institutes of Health, National Human Genome Research Institute (NHGRI) 2022 report, the FY 2022 United States President's Budget request is USD 633.0 million, an increase of USD 17.0 million compared with the FY 2021 enacted level. This increase is distributed across all programmatic areas and basic, epidemiology, and clinical research across genomics. To improve human health, NHGRI interacts with a variety of groups, performs and funds genomics research, and educates the next generation of genomics specialists. The huge investment by the NHGRI in the genomics study is expected to utilize a large amount of restriction enzymes during the research, which is expected to propel the market growth during the forecast period.

Also, in September 2022, WhiteLab Genomics raised USD 10 million for an AI-powered genomic therapies platform. The investment is intended to revolutionize the creation of genetic therapies. The company supports its clients to enable them to quickly develop target vectors and payloads and bring genomic-based therapies to market at a faster pace. Hence, the funding and investments are estimated to create opportunities for expansion and innovation in the field of genetic engineering, DNA mapping, and gene sequencing using the restriction endonucleases, which further propels the market growth.

Therefore, owing to the factors such as the utility of restriction endonucleases in various research applications and funding and investment by pharmaceutical and biotechnology companies, the studied market is anticipated to witness growth over the analysis period.

However, the high cost of restriction enzyme production is likely to impede the market growth over the forecast period,

Restriction Endonucleases Industry Overview

The Restriction Endonucleases Market is moderately competitive and consists of several major players. Some companies currently dominating the market are Agilent Technologies, Thermo Fisher Scientific, Illumina Inc., New England Biolabs, Merck KGaA, Promega Corporation, Takara Bio Inc., QIAGEN NV, GenScript, and TransGen Biotech Co., Ltd.

Restriction Endonucleases Market Leaders

  1. Agilent Technologies

  2. Thermo Fisher Scientific

  3. Illumina, Inc.

  4. New England Biolabs

  5. Merck KGaA

  6. *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competiters?
Download PDF

Restriction Endonucleases Market News

  • August 2022: Diagnostics and research startup MedGenome raised USD 50.0 million led by life science-focused Novo Holdings. The company uses genomic sequencing platforms to aid in diagnostics and drug discovery. The genomic sequencing drug discovery deploys the use of restriction endonucleases.
  • March 2022: Roche CustomBiotech launched Restriction enzyme Xba I, which is used upstream of the in-vitro mRNA synthesis step during mRNA therapeutics and vaccine manufacturing.

Restriction Endonucleases Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Use of Restriction Endonucleases in Various Applications
    • 4.2.2 Increasing Expenditure on Research and Development by Biotechnology and Pharmaceutical Companies.
  • 4.3 Market Restraints
    • 4.3.1 High Cost Restriction Endonucleases Production
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD)

  • 5.1 By Type
    • 5.1.1 Type I
    • 5.1.2 Type II
    • 5.1.3 Type III
    • 5.1.4 Other Types
  • 5.2 By Application
    • 5.2.1 Genetic Engineering
    • 5.2.2 DNA Mapping
    • 5.2.3 Gene Sequencing
    • 5.2.4 Other Applications
  • 5.3 By End User
    • 5.3.1 Pharmaceutical and Biotechnology Companies
    • 5.3.2 Academic Research Institutes
    • 5.3.3 Other End Users
  • 5.4 Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Rest of the World

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Agilent Technologies
    • 6.1.2 Thermo Fisher Scientific
    • 6.1.3 Illumina Inc.
    • 6.1.4 New England Biolabs
    • 6.1.5 Merck KGaA
    • 6.1.6 Promega Corporation
    • 6.1.7 Takara Bio Inc.
    • 6.1.8 QIAGEN NV
    • 6.1.9 GenScript
    • 6.1.10 TransGen Biotech Co., Ltd.
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Restriction Endonucleases Industry Segmentation

The restriction endonuclease is an enzyme that cuts the DNA molecule at, or near to, a specific nucleotide sequence to produce discrete DNA fragments that can be separated by gel electrophoresis.

As per the scope of the report, the Restriction Endonucleases Market is Segmented by Type (Type I, Type II, Type III, and Type IV), Application (Genetic Engineering, DNA Mapping, Gene Sequencing, and Other Applications), End User (Pharmaceutical and Biotechnology Companies, Academic Research Institutes, and Other End Users), and Geography (North America, Europe, Asia-Pacific, and Rest of the World). The market report also covers the estimated market sizes and trends for 13 different countries across major regions, globally. The report offers the value (USD) for the above segments.

By Type Type I
Type II
Type III
Other Types
By Application Genetic Engineering
DNA Mapping
Gene Sequencing
Other Applications
By End User Pharmaceutical and Biotechnology Companies
Academic Research Institutes
Other End Users
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Rest of the World
Need A Different Region or Segment?
Customize Now

Restriction Endonucleases Market Research FAQs

How big is the Restriction Endonucleases Market?

The Restriction Endonucleases Market size is expected to reach USD 328.95 million in 2025 and grow at a CAGR of 6.67% to reach USD 454.30 million by 2030.

What is the current Restriction Endonucleases Market size?

In 2025, the Restriction Endonucleases Market size is expected to reach USD 328.95 million.

Who are the key players in Restriction Endonucleases Market?

Agilent Technologies, Thermo Fisher Scientific, Illumina, Inc., New England Biolabs and Merck KGaA are the major companies operating in the Restriction Endonucleases Market.

Which is the fastest growing region in Restriction Endonucleases Market?

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Restriction Endonucleases Market?

In 2025, the North America accounts for the largest market share in Restriction Endonucleases Market.

What years does this Restriction Endonucleases Market cover, and what was the market size in 2024?

In 2024, the Restriction Endonucleases Market size was estimated at USD 307.01 million. The report covers the Restriction Endonucleases Market historical market size for years: 2024. The report also forecasts the Restriction Endonucleases Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Bone Grafts and Substitutes Industry Report

Statistics for the 2025 Restriction Endonucleases market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Restriction Endonucleases analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.

Restriction Enzyme Market Report Snapshots

Restriction Endonucleases Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)